BIOMAT Database Logo BIOMAT Database Logo

Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience. 1991

B Shapiro, and J C Sisson, and D M Wieland, and T J Mangner, and S M Zempel, and E Mudgett, and M D Gross, and J E Carey, and K R Zasadny, and W H Beierwaltes
Department of Internal Medicine, University of Michigan, Ann Arbor 48109-0028.

Twenty-eight patients with histologically proven metastatic or invasive, unresectable pheochromocytomas, which were shown to concentrate and retain tracer doses of [131I]metaiodobenzylguanidine (131I-MIBG), were treated with therapeutic quantities of this radiopharmaceutical. Between one and six doses ranging from 97 to 301 mCi (cumulative dose 111-916 mCi) were administered. Partial response in tumor size was achieved in 8/28 patients and partial biochemical responses in 12/28 patients. No pharmacological toxicity was observed. Mild radiation sickness (nausea, vomiting, anorexia) occurred in 21/28. Minor degrees of leukopenia and thrombocytopenia were observed in 3/28. There were three cases of hypothyroidism but no significant hepatic, renal, adrenocortical or autonomic nervous dysfunction. We conclude that therapeutic 131I-MIBG can achieve significant therapeutic responses in some cases of malignant pheochromocytoma without pharmacological toxicity and only mild radiotoxicity.

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D007462 Iodobenzenes Any derivative of BENZENE that contains IODINE.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010673 Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298) Pheochromocytoma, Extra-Adrenal,Extra-Adrenal Pheochromocytoma,Extra-Adrenal Pheochromocytomas,Pheochromocytoma, Extra Adrenal,Pheochromocytomas,Pheochromocytomas, Extra-Adrenal
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000310 Adrenal Gland Neoplasms Tumors or cancer of the ADRENAL GLANDS. Adrenal Cancer,Adrenal Gland Cancer,Adrenal Neoplasm,Cancer of the Adrenal Gland,Neoplasms, Adrenal Gland,Adrenal Cancers,Adrenal Gland Cancers,Adrenal Gland Neoplasm,Adrenal Neoplasms,Cancer, Adrenal,Cancer, Adrenal Gland,Cancers, Adrenal,Cancers, Adrenal Gland,Neoplasm, Adrenal,Neoplasm, Adrenal Gland,Neoplasms, Adrenal

Related Publications

B Shapiro, and J C Sisson, and D M Wieland, and T J Mangner, and S M Zempel, and E Mudgett, and M D Gross, and J E Carey, and K R Zasadny, and W H Beierwaltes
131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma.
May 1994, Annals of nuclear medicine,
B Shapiro, and J C Sisson, and D M Wieland, and T J Mangner, and S M Zempel, and E Mudgett, and M D Gross, and J E Carey, and K R Zasadny, and W H Beierwaltes
Results of [131I]metaiodobenzylguanidine therapy administered to three patients with malignant pheochromocytoma.
January 1991, Journal of nuclear biology and medicine (Turin, Italy : 1991),
B Shapiro, and J C Sisson, and D M Wieland, and T J Mangner, and S M Zempel, and E Mudgett, and M D Gross, and J E Carey, and K R Zasadny, and W H Beierwaltes
[131I]metaiodobenzylguanidine therapy in 20 patients with malignant pheochromocytoma.
January 1991, Journal of nuclear biology and medicine (Turin, Italy : 1991),
B Shapiro, and J C Sisson, and D M Wieland, and T J Mangner, and S M Zempel, and E Mudgett, and M D Gross, and J E Carey, and K R Zasadny, and W H Beierwaltes
Therapy of pheochromocytoma with [131I]metaiodobenzylguanidine.
January 1991, Journal of nuclear biology and medicine (Turin, Italy : 1991),
B Shapiro, and J C Sisson, and D M Wieland, and T J Mangner, and S M Zempel, and E Mudgett, and M D Gross, and J E Carey, and K R Zasadny, and W H Beierwaltes
[131I]metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication.
January 1991, Journal of nuclear biology and medicine (Turin, Italy : 1991),
B Shapiro, and J C Sisson, and D M Wieland, and T J Mangner, and S M Zempel, and E Mudgett, and M D Gross, and J E Carey, and K R Zasadny, and W H Beierwaltes
Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma.
October 2005, The Journal of clinical endocrinology and metabolism,
B Shapiro, and J C Sisson, and D M Wieland, and T J Mangner, and S M Zempel, and E Mudgett, and M D Gross, and J E Carey, and K R Zasadny, and W H Beierwaltes
High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
July 2003, Cancer,
B Shapiro, and J C Sisson, and D M Wieland, and T J Mangner, and S M Zempel, and E Mudgett, and M D Gross, and J E Carey, and K R Zasadny, and W H Beierwaltes
[131I]metaiodobenzylguanidine treatment of malignant pheochromocytoma: experience of the Rome group.
January 1991, Journal of nuclear biology and medicine (Turin, Italy : 1991),
B Shapiro, and J C Sisson, and D M Wieland, and T J Mangner, and S M Zempel, and E Mudgett, and M D Gross, and J E Carey, and K R Zasadny, and W H Beierwaltes
A case of malignant pheochromocytoma treated by 131I-metaiodobenzylguanidine.
January 1988, Acta oncologica (Stockholm, Sweden),
B Shapiro, and J C Sisson, and D M Wieland, and T J Mangner, and S M Zempel, and E Mudgett, and M D Gross, and J E Carey, and K R Zasadny, and W H Beierwaltes
Treatment of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: a French multicenter study.
January 1991, Journal of nuclear biology and medicine (Turin, Italy : 1991),
Copied contents to your clipboard!